158 related articles for article (PubMed ID: 12902896)
41. Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old.
Italiano A; Jardin F; Peyrade F; Saudes L; Tilly H; Thyss A
Haematologica; 2005 Sep; 90(9):1281-3. PubMed ID: 16154857
[TBL] [Abstract][Full Text] [Related]
42. Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience.
Biswas G; Parikh PM; Nair R; Bhagwat R; Bakshi A; Prabhash K; Vora A; Gupta S; Pai VR; Menon H; Sastry PS
J Assoc Physicians India; 2006 Jan; 54():29-33. PubMed ID: 16649735
[TBL] [Abstract][Full Text] [Related]
43. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
44. New concepts in treatment approaches and prognostic factors in aggressive NHL.
Shipp M
Clin Adv Hematol Oncol; 2006 Feb; 4(2):107-9. PubMed ID: 16728917
[No Abstract] [Full Text] [Related]
45. [Monoclonal antibody therapy for malignant lymphoma].
Buske C; Dreyling M; Unterhalt M; Hiddemann W
Med Klin (Munich); 2005 Jan; 100(1):14-24. PubMed ID: 15654538
[TBL] [Abstract][Full Text] [Related]
46. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
Niitsu N; Hayama M; Okamoto M; Khori M; Higashihara M; Tamaru J; Hirano M
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4077-82. PubMed ID: 15217942
[TBL] [Abstract][Full Text] [Related]
47. Ibritumomab: new drug. Interesting concept, disappointing in practice.
Prescrire Int; 2005 Oct; 14(79):171-3. PubMed ID: 16285071
[TBL] [Abstract][Full Text] [Related]
48. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
[TBL] [Abstract][Full Text] [Related]
49. Clinical investigations in aggressive non-Hodgkin lymphoma.
Jonathan F
Clin Adv Hematol Oncol; 2008 Sep; 6(9):7-8. PubMed ID: 18998259
[No Abstract] [Full Text] [Related]
50. Rapid infusion rituximab changing practice for patient care.
Al Zahrani A; Ibrahim N; Al Eid A
J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
[TBL] [Abstract][Full Text] [Related]
51. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
[TBL] [Abstract][Full Text] [Related]
52. Partial remission of psoriasis following rituximab therapy for non-Hodgkin lymphoma.
Singh F; Weinberg JM
Cutis; 2005 Sep; 76(3):186-8. PubMed ID: 16268262
[TBL] [Abstract][Full Text] [Related]
53. [A case of follicular lymphoma of the duodenum treated with the combined therapy of anti-CD20 antibody and chemotherapy].
Isogai K; Yamamoto E; Yamaoka S; Tarasawa I; Murakami R; Morimoto I; Obata T; Mori M; Endo T; Imai K
Nihon Shokakibyo Gakkai Zasshi; 2006 Mar; 103(3):301-9. PubMed ID: 16688961
[No Abstract] [Full Text] [Related]
54. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus.
Borradori L; Lombardi T; Samson J; Girardet C; Saurat JH; Hügli A
Arch Dermatol; 2001 Mar; 137(3):269-72. PubMed ID: 11255323
[No Abstract] [Full Text] [Related]
55. CD20-negative relapse after (131)I-anti-CD20 therapy.
Venugopal P; Leslie WT; O'Brien T; Gregory SA
J Clin Oncol; 1999 Nov; 17(11):3692-3. PubMed ID: 10550173
[No Abstract] [Full Text] [Related]
56. Novel CD20 monoclonal antibodies for lymphoma therapy.
Cang S; Mukhi N; Wang K; Liu D
J Hematol Oncol; 2012 Oct; 5():64. PubMed ID: 23057966
[TBL] [Abstract][Full Text] [Related]
57. Clinical trials referral resource. Current clinical trials of the anti-CD20 monoclonal antibody rituximab.
Davis T; Gore-Langton RE; Cheson BD
Oncology (Williston Park); 2000 Oct; 14(10):1437, 1440-3. PubMed ID: 11098509
[No Abstract] [Full Text] [Related]
58. Primary duodenal follicular lymphoma successfully treated with rituximab.
Aguiar-Bujanda D; Quiñones-Morales I; Camacho-Galán R; Llorca-Martínez I; Rivero-Vera JC; Bohn-Sarmiento U; Aguiar-Morales J
Clin Transl Oncol; 2007 Jul; 9(7):471-2. PubMed ID: 17652063
[TBL] [Abstract][Full Text] [Related]
59. [Intestinal lymphoma presented as multiple intestinal polyposis].
Norum J; Wist E
Tidsskr Nor Laegeforen; 1992 Jun; 112(15):1956-7. PubMed ID: 1509456
[TBL] [Abstract][Full Text] [Related]
60. Treatment of pharyngeal non-Hodgkin lymphoma in a patient with Wiskott-Aldrich syndrome.
Coccia P; Mastrangelo S; Ruggiero A; Scalzone M; Rosolen A; Maurizi P; Riccardi R
Pediatr Blood Cancer; 2012 Aug; 59(2):318-9. PubMed ID: 22052860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
